Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple supplement tame a stubborn heart risk?

NCT ID NCT07198009

Disease control Sponsor: The Miriam Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether a natural supplement called 2-HOBA can reduce harmful oxidized fats in people with high lipoprotein(a), a genetic risk factor for heart disease. Ten adults with elevated Lp(a) will take 2-HOBA capsules for 6 weeks. Researchers will measure changes in blood markers of oxidation, inflammation, and clotting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
2-HOBA (Hobamine), a dietary supplement
What this could lead to
If it works, this could point toward a simple supplement to lower heart disease risk in people with high lipoprotein(a).
What could go wrong
This is a very small, early pilot study with only 10 participants and no placebo group, so results may not be conclusive or generalizable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2025

An estimate. Start dates often move.

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 69 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males and females aged 18-69 years. * Elevated Lp(a) levels ≥ 90 mg/dL. * Able to provide informed consent and adhere to study schedules. * Willing to follow a physician-recommended diet during the study. Exclusion Criteria: * Pregnant, planning pregnancy during the study period, or currently breastfeeding. * Individuals with established cardiovascular disease * Planning major changes in diet or exercise routines. * Experienced \>20% weight change in the past 3 months. * Diagnosed with malabsorption syndrome or chronic diarrhea. * Abnormal liver, kidney, or thyroid function. * Drug or alcohol abuse within the past 6 months, or significant mental/psychological impairment. * Have known bleeding disorders (e.g., hemophilia). * Planned surgery during the study period. * Donated blood within the last 2 weeks or planning to donate during the study. * Require regular blood transfusions.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Elevated LP(A) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hyperlipidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Elevated LP(A) Hyperlipidemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Lipid Clinic at Brown University Health

    Providence, Rhode Island, 02914, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.